nodes	percent_of_prediction	percent_of_DWPC	metapath
Lidocaine—SLC22A5—Dactinomycin—muscle cancer	0.188	0.245	CbGbCtD
Lidocaine—CYP1A2—Dacarbazine—muscle cancer	0.063	0.0821	CbGbCtD
Lidocaine—CYP3A7—Vincristine—muscle cancer	0.0603	0.0785	CbGbCtD
Lidocaine—CYP3A7-CYP3A51P—Vincristine—muscle cancer	0.0603	0.0785	CbGbCtD
Lidocaine—ABCB1—Dactinomycin—muscle cancer	0.0478	0.0622	CbGbCtD
Lidocaine—CYP3A5—Vincristine—muscle cancer	0.0452	0.0589	CbGbCtD
Lidocaine—CYP3A5—Etoposide—muscle cancer	0.0414	0.054	CbGbCtD
Lidocaine—CYP2C8—Etoposide—muscle cancer	0.0398	0.0519	CbGbCtD
Lidocaine—CYP2B6—Doxorubicin—muscle cancer	0.0359	0.0467	CbGbCtD
Lidocaine—CYP1A2—Etoposide—muscle cancer	0.0308	0.0402	CbGbCtD
Lidocaine—ABCB1—Vincristine—muscle cancer	0.0294	0.0383	CbGbCtD
Lidocaine—ABCB1—Etoposide—muscle cancer	0.027	0.0351	CbGbCtD
Lidocaine—ABCB1—Doxorubicin—muscle cancer	0.0184	0.024	CbGbCtD
Lidocaine—ABCB1—Methotrexate—muscle cancer	0.0178	0.0232	CbGbCtD
Lidocaine—CYP3A4—Vincristine—muscle cancer	0.0176	0.023	CbGbCtD
Lidocaine—CYP2D6—Doxorubicin—muscle cancer	0.0173	0.0226	CbGbCtD
Lidocaine—CYP3A4—Etoposide—muscle cancer	0.0162	0.021	CbGbCtD
Lidocaine—Cranial nerve paralysis—Vincristine—muscle cancer	0.0131	0.0782	CcSEcCtD
Lidocaine—CYP3A4—Doxorubicin—muscle cancer	0.011	0.0144	CbGbCtD
Lidocaine—CNS toxicity—Etoposide—muscle cancer	0.0106	0.0633	CcSEcCtD
Lidocaine—CNS toxicity—Methotrexate—muscle cancer	0.00636	0.0379	CcSEcCtD
Lidocaine—Cranial nerve paralysis—Methotrexate—muscle cancer	0.00636	0.0379	CcSEcCtD
Lidocaine—Meningism—Methotrexate—muscle cancer	0.00423	0.0252	CcSEcCtD
Lidocaine—Arachnoiditis—Methotrexate—muscle cancer	0.00402	0.0239	CcSEcCtD
Lidocaine—Neurotoxicity—Vincristine—muscle cancer	0.0039	0.0232	CcSEcCtD
Lidocaine—Neurotoxicity—Etoposide—muscle cancer	0.00316	0.0188	CcSEcCtD
Lidocaine—Taste metallic—Methotrexate—muscle cancer	0.00231	0.0138	CcSEcCtD
Lidocaine—Paralysis—Vincristine—muscle cancer	0.00218	0.013	CcSEcCtD
Lidocaine—Neurotoxicity—Methotrexate—muscle cancer	0.00189	0.0113	CcSEcCtD
Lidocaine—Numbness—Vincristine—muscle cancer	0.00182	0.0109	CcSEcCtD
Lidocaine—Sensory loss—Vincristine—muscle cancer	0.00174	0.0104	CcSEcCtD
Lidocaine—Leukoderma—Methotrexate—muscle cancer	0.00173	0.0103	CcSEcCtD
Lidocaine—Laryngospasm—Etoposide—muscle cancer	0.00164	0.00978	CcSEcCtD
Lidocaine—Neurotoxicity—Doxorubicin—muscle cancer	0.00164	0.00977	CcSEcCtD
Lidocaine—Leukoderma—Doxorubicin—muscle cancer	0.00149	0.00891	CcSEcCtD
Lidocaine—Numbness—Etoposide—muscle cancer	0.00148	0.00881	CcSEcCtD
Lidocaine—Apnoea—Etoposide—muscle cancer	0.00144	0.00861	CcSEcCtD
Lidocaine—Neuropathy—Vincristine—muscle cancer	0.00142	0.00846	CcSEcCtD
Lidocaine—Sensory loss—Etoposide—muscle cancer	0.00141	0.00843	CcSEcCtD
Lidocaine—Coma—Vincristine—muscle cancer	0.00138	0.00823	CcSEcCtD
Lidocaine—Skin exfoliation—Etoposide—muscle cancer	0.00117	0.00697	CcSEcCtD
Lidocaine—Neuropathy—Etoposide—muscle cancer	0.00115	0.00685	CcSEcCtD
Lidocaine—Local reaction—Doxorubicin—muscle cancer	0.00115	0.00684	CcSEcCtD
Lidocaine—Dysphagia—Dactinomycin—muscle cancer	0.00106	0.00633	CcSEcCtD
Lidocaine—Paralysis—Methotrexate—muscle cancer	0.00106	0.00629	CcSEcCtD
Lidocaine—Burning sensation—Methotrexate—muscle cancer	0.00106	0.00629	CcSEcCtD
Lidocaine—Cardiac arrest—Vincristine—muscle cancer	0.00104	0.00622	CcSEcCtD
Lidocaine—Urinary retention—Vincristine—muscle cancer	0.00104	0.00622	CcSEcCtD
Lidocaine—Redness—Doxorubicin—muscle cancer	0.000941	0.00561	CcSEcCtD
Lidocaine—Gingivitis—Methotrexate—muscle cancer	0.000934	0.00557	CcSEcCtD
Lidocaine—Stomatitis—Dactinomycin—muscle cancer	0.000922	0.0055	CcSEcCtD
Lidocaine—Anaphylactoid reaction—Etoposide—muscle cancer	0.000918	0.00548	CcSEcCtD
Lidocaine—Paralysis—Doxorubicin—muscle cancer	0.000914	0.00545	CcSEcCtD
Lidocaine—Burning sensation—Doxorubicin—muscle cancer	0.000914	0.00545	CcSEcCtD
Lidocaine—Petechiae—Methotrexate—muscle cancer	0.000891	0.00531	CcSEcCtD
Lidocaine—Blister—Doxorubicin—muscle cancer	0.000881	0.00525	CcSEcCtD
Lidocaine—Apnoea—Methotrexate—muscle cancer	0.000865	0.00516	CcSEcCtD
Lidocaine—Cardiac arrest—Etoposide—muscle cancer	0.000845	0.00504	CcSEcCtD
Lidocaine—Neuropathy peripheral—Vincristine—muscle cancer	0.000829	0.00494	CcSEcCtD
Lidocaine—Stomatitis—Vincristine—muscle cancer	0.000824	0.00491	CcSEcCtD
Lidocaine—Hyperaesthesia—Doxorubicin—muscle cancer	0.000809	0.00482	CcSEcCtD
Lidocaine—Feeling hot—Doxorubicin—muscle cancer	0.000809	0.00482	CcSEcCtD
Lidocaine—Gingivitis—Doxorubicin—muscle cancer	0.000809	0.00482	CcSEcCtD
Lidocaine—Flushing—Dactinomycin—muscle cancer	0.000788	0.0047	CcSEcCtD
Lidocaine—Dysarthria—Methotrexate—muscle cancer	0.000775	0.00462	CcSEcCtD
Lidocaine—Dysphonia—Doxorubicin—muscle cancer	0.000772	0.0046	CcSEcCtD
Lidocaine—Petechiae—Doxorubicin—muscle cancer	0.000772	0.0046	CcSEcCtD
Lidocaine—Dysphagia—Etoposide—muscle cancer	0.000768	0.00458	CcSEcCtD
Lidocaine—Chills—Dactinomycin—muscle cancer	0.000762	0.00454	CcSEcCtD
Lidocaine—Bronchospasm—Etoposide—muscle cancer	0.000756	0.0045	CcSEcCtD
Lidocaine—Hypoaesthesia—Vincristine—muscle cancer	0.000755	0.0045	CcSEcCtD
Lidocaine—Sweating increased—Etoposide—muscle cancer	0.000748	0.00446	CcSEcCtD
Lidocaine—Erythema—Dactinomycin—muscle cancer	0.000739	0.00441	CcSEcCtD
Lidocaine—Depressed level of consciousness—Methotrexate—muscle cancer	0.000708	0.00422	CcSEcCtD
Lidocaine—Cardiac disorder—Vincristine—muscle cancer	0.000704	0.0042	CcSEcCtD
Lidocaine—Skin exfoliation—Methotrexate—muscle cancer	0.0007	0.00417	CcSEcCtD
Lidocaine—Angiopathy—Vincristine—muscle cancer	0.000689	0.00411	CcSEcCtD
Lidocaine—Dysarthria—Doxorubicin—muscle cancer	0.000671	0.004	CcSEcCtD
Lidocaine—Neuropathy peripheral—Etoposide—muscle cancer	0.000671	0.004	CcSEcCtD
Lidocaine—Coma—Methotrexate—muscle cancer	0.00067	0.004	CcSEcCtD
Lidocaine—Stomatitis—Etoposide—muscle cancer	0.000668	0.00398	CcSEcCtD
Lidocaine—Atrioventricular block—Doxorubicin—muscle cancer	0.000655	0.0039	CcSEcCtD
Lidocaine—SCN4A—renal system—muscle cancer	0.000646	0.0469	CbGeAlD
Lidocaine—Back pain—Vincristine—muscle cancer	0.000639	0.00381	CcSEcCtD
Lidocaine—Ventricular tachycardia—Doxorubicin—muscle cancer	0.000635	0.00379	CcSEcCtD
Lidocaine—Dermatitis contact—Doxorubicin—muscle cancer	0.000628	0.00374	CcSEcCtD
Lidocaine—Hypoaesthesia—Etoposide—muscle cancer	0.000612	0.00365	CcSEcCtD
Lidocaine—Agitation—Vincristine—muscle cancer	0.000607	0.00362	CcSEcCtD
Lidocaine—Skin exfoliation—Doxorubicin—muscle cancer	0.000606	0.00361	CcSEcCtD
Lidocaine—Oedema—Dactinomycin—muscle cancer	0.000604	0.0036	CcSEcCtD
Lidocaine—Neuropathy—Doxorubicin—muscle cancer	0.000596	0.00355	CcSEcCtD
Lidocaine—Coma—Doxorubicin—muscle cancer	0.00058	0.00346	CcSEcCtD
Lidocaine—Eye disorder—Etoposide—muscle cancer	0.000575	0.00343	CcSEcCtD
Lidocaine—Convulsion—Vincristine—muscle cancer	0.000572	0.00341	CcSEcCtD
Lidocaine—Flushing—Etoposide—muscle cancer	0.000571	0.0034	CcSEcCtD
Lidocaine—Cardiac disorder—Etoposide—muscle cancer	0.000571	0.0034	CcSEcCtD
Lidocaine—Hypertension—Vincristine—muscle cancer	0.00057	0.0034	CcSEcCtD
Lidocaine—EGFR—testis—muscle cancer	0.000568	0.0413	CbGeAlD
Lidocaine—SCN9A—tendon—muscle cancer	0.000565	0.0411	CbGeAlD
Lidocaine—Visual disturbance—Methotrexate—muscle cancer	0.000562	0.00335	CcSEcCtD
Lidocaine—Angiopathy—Etoposide—muscle cancer	0.000558	0.00333	CcSEcCtD
Lidocaine—Immune system disorder—Etoposide—muscle cancer	0.000555	0.00331	CcSEcCtD
Lidocaine—Chills—Etoposide—muscle cancer	0.000552	0.00329	CcSEcCtD
Lidocaine—CYP2C18—vagina—muscle cancer	0.00055	0.04	CbGeAlD
Lidocaine—Anaphylactoid reaction—Methotrexate—muscle cancer	0.00055	0.00328	CcSEcCtD
Lidocaine—Anaphylactic shock—Vincristine—muscle cancer	0.000539	0.00322	CcSEcCtD
Lidocaine—Oedema—Vincristine—muscle cancer	0.000539	0.00322	CcSEcCtD
Lidocaine—Osteoarthritis—Methotrexate—muscle cancer	0.000532	0.00317	CcSEcCtD
Lidocaine—Nervous system disorder—Vincristine—muscle cancer	0.000529	0.00315	CcSEcCtD
Lidocaine—Dysgeusia—Etoposide—muscle cancer	0.000524	0.00313	CcSEcCtD
Lidocaine—Hyperhidrosis—Vincristine—muscle cancer	0.000521	0.00311	CcSEcCtD
Lidocaine—Back pain—Etoposide—muscle cancer	0.000518	0.00309	CcSEcCtD
Lidocaine—Pain—Dactinomycin—muscle cancer	0.000516	0.00308	CcSEcCtD
Lidocaine—SCN4A—tendon—muscle cancer	0.000504	0.0366	CbGeAlD
Lidocaine—Hypotension—Vincristine—muscle cancer	0.000504	0.003	CcSEcCtD
Lidocaine—SCN3A—renal system—muscle cancer	0.000503	0.0365	CbGeAlD
Lidocaine—Feeling abnormal—Dactinomycin—muscle cancer	0.000497	0.00297	CcSEcCtD
Lidocaine—Paraesthesia—Vincristine—muscle cancer	0.000484	0.00289	CcSEcCtD
Lidocaine—Dermatitis bullous—Doxorubicin—muscle cancer	0.000482	0.00288	CcSEcCtD
Lidocaine—Anaphylactoid reaction—Doxorubicin—muscle cancer	0.000476	0.00284	CcSEcCtD
Lidocaine—Loss of consciousness—Etoposide—muscle cancer	0.00047	0.0028	CcSEcCtD
Lidocaine—SCN9A—testis—muscle cancer	0.000468	0.034	CbGeAlD
Lidocaine—Gastrointestinal disorder—Vincristine—muscle cancer	0.000466	0.00278	CcSEcCtD
Lidocaine—Convulsion—Etoposide—muscle cancer	0.000464	0.00276	CcSEcCtD
Lidocaine—Hypertension—Etoposide—muscle cancer	0.000462	0.00276	CcSEcCtD
Lidocaine—Pain—Vincristine—muscle cancer	0.000461	0.00275	CcSEcCtD
Lidocaine—Diplopia—Doxorubicin—muscle cancer	0.000461	0.00275	CcSEcCtD
Lidocaine—Osteoarthritis—Doxorubicin—muscle cancer	0.000461	0.00275	CcSEcCtD
Lidocaine—Asthma—Methotrexate—muscle cancer	0.00046	0.00274	CcSEcCtD
Lidocaine—Chest pain—Etoposide—muscle cancer	0.000456	0.00272	CcSEcCtD
Lidocaine—SCN5A—cardiac atrium—muscle cancer	0.000449	0.0326	CbGeAlD
Lidocaine—Hypersensitivity—Dactinomycin—muscle cancer	0.000445	0.00265	CcSEcCtD
Lidocaine—Confusional state—Etoposide—muscle cancer	0.00044	0.00263	CcSEcCtD
Lidocaine—Cardiac arrest—Doxorubicin—muscle cancer	0.000438	0.00261	CcSEcCtD
Lidocaine—Anaphylactic shock—Etoposide—muscle cancer	0.000437	0.0026	CcSEcCtD
Lidocaine—Asthenia—Dactinomycin—muscle cancer	0.000433	0.00258	CcSEcCtD
Lidocaine—SCN4A—head—muscle cancer	0.000432	0.0314	CbGeAlD
Lidocaine—Hyperhidrosis—Etoposide—muscle cancer	0.000422	0.00252	CcSEcCtD
Lidocaine—SCN4A—testis—muscle cancer	0.000418	0.0303	CbGeAlD
Lidocaine—SCN2A—vagina—muscle cancer	0.000414	0.0301	CbGeAlD
Lidocaine—Drowsiness—Methotrexate—muscle cancer	0.00041	0.00245	CcSEcCtD
Lidocaine—Hypotension—Etoposide—muscle cancer	0.000408	0.00243	CcSEcCtD
Lidocaine—Stomatitis—Methotrexate—muscle cancer	0.0004	0.00238	CcSEcCtD
Lidocaine—Asthma—Doxorubicin—muscle cancer	0.000398	0.00238	CcSEcCtD
Lidocaine—Dysphagia—Doxorubicin—muscle cancer	0.000398	0.00238	CcSEcCtD
Lidocaine—Hypersensitivity—Vincristine—muscle cancer	0.000397	0.00237	CcSEcCtD
Lidocaine—SCN3A—tendon—muscle cancer	0.000392	0.0285	CbGeAlD
Lidocaine—Paraesthesia—Etoposide—muscle cancer	0.000392	0.00234	CcSEcCtD
Lidocaine—Dyspnoea—Etoposide—muscle cancer	0.000389	0.00232	CcSEcCtD
Lidocaine—Somnolence—Etoposide—muscle cancer	0.000388	0.00232	CcSEcCtD
Lidocaine—Asthenia—Vincristine—muscle cancer	0.000387	0.00231	CcSEcCtD
Lidocaine—Vomiting—Dactinomycin—muscle cancer	0.000384	0.00229	CcSEcCtD
Lidocaine—SCN2A—head—muscle cancer	0.000383	0.0278	CbGeAlD
Lidocaine—Rash—Dactinomycin—muscle cancer	0.000381	0.00227	CcSEcCtD
Lidocaine—SCN3A—bone marrow—muscle cancer	0.00038	0.0276	CbGeAlD
Lidocaine—Gastrointestinal disorder—Etoposide—muscle cancer	0.000377	0.00225	CcSEcCtD
Lidocaine—Pain—Etoposide—muscle cancer	0.000374	0.00223	CcSEcCtD
Lidocaine—Haemoglobin—Methotrexate—muscle cancer	0.00037	0.00221	CcSEcCtD
Lidocaine—SCN10A—head—muscle cancer	0.000369	0.0268	CbGeAlD
Lidocaine—Haemorrhage—Methotrexate—muscle cancer	0.000368	0.0022	CcSEcCtD
Lidocaine—SCN3A—vagina—muscle cancer	0.000364	0.0264	CbGeAlD
Lidocaine—CYP2A6—vagina—muscle cancer	0.000364	0.0264	CbGeAlD
Lidocaine—SCN5A—vagina—muscle cancer	0.000363	0.0264	CbGeAlD
Lidocaine—Feeling abnormal—Etoposide—muscle cancer	0.00036	0.00215	CcSEcCtD
Lidocaine—Nausea—Dactinomycin—muscle cancer	0.000358	0.00214	CcSEcCtD
Lidocaine—Dizziness—Vincristine—muscle cancer	0.000357	0.00213	CcSEcCtD
Lidocaine—Drowsiness—Doxorubicin—muscle cancer	0.000355	0.00212	CcSEcCtD
Lidocaine—Visual impairment—Methotrexate—muscle cancer	0.000355	0.00212	CcSEcCtD
Lidocaine—Neuropathy peripheral—Doxorubicin—muscle cancer	0.000348	0.00208	CcSEcCtD
Lidocaine—Urticaria—Etoposide—muscle cancer	0.000347	0.00207	CcSEcCtD
Lidocaine—Stomatitis—Doxorubicin—muscle cancer	0.000346	0.00206	CcSEcCtD
Lidocaine—Eye disorder—Methotrexate—muscle cancer	0.000344	0.00205	CcSEcCtD
Lidocaine—Tinnitus—Methotrexate—muscle cancer	0.000343	0.00205	CcSEcCtD
Lidocaine—Vomiting—Vincristine—muscle cancer	0.000343	0.00204	CcSEcCtD
Lidocaine—Cardiac disorder—Methotrexate—muscle cancer	0.000342	0.00204	CcSEcCtD
Lidocaine—Rash—Vincristine—muscle cancer	0.00034	0.00203	CcSEcCtD
Lidocaine—Dermatitis—Vincristine—muscle cancer	0.00034	0.00203	CcSEcCtD
Lidocaine—Headache—Vincristine—muscle cancer	0.000338	0.00201	CcSEcCtD
Lidocaine—SCN3A—head—muscle cancer	0.000336	0.0244	CbGeAlD
Lidocaine—SCN5A—head—muscle cancer	0.000335	0.0244	CbGeAlD
Lidocaine—Angiopathy—Methotrexate—muscle cancer	0.000334	0.00199	CcSEcCtD
Lidocaine—Immune system disorder—Methotrexate—muscle cancer	0.000333	0.00198	CcSEcCtD
Lidocaine—Chills—Methotrexate—muscle cancer	0.00033	0.00197	CcSEcCtD
Lidocaine—SCN3A—testis—muscle cancer	0.000325	0.0236	CbGeAlD
Lidocaine—Bradycardia—Doxorubicin—muscle cancer	0.000325	0.00194	CcSEcCtD
Lidocaine—Hypersensitivity—Etoposide—muscle cancer	0.000322	0.00192	CcSEcCtD
Lidocaine—Erythema—Methotrexate—muscle cancer	0.000321	0.00191	CcSEcCtD
Lidocaine—Haemoglobin—Doxorubicin—muscle cancer	0.00032	0.00191	CcSEcCtD
Lidocaine—Nausea—Vincristine—muscle cancer	0.00032	0.00191	CcSEcCtD
Lidocaine—Rhinitis—Doxorubicin—muscle cancer	0.00032	0.00191	CcSEcCtD
Lidocaine—Haemorrhage—Doxorubicin—muscle cancer	0.000319	0.0019	CcSEcCtD
Lidocaine—Hypoaesthesia—Doxorubicin—muscle cancer	0.000317	0.00189	CcSEcCtD
Lidocaine—Dysgeusia—Methotrexate—muscle cancer	0.000314	0.00187	CcSEcCtD
Lidocaine—Asthenia—Etoposide—muscle cancer	0.000313	0.00187	CcSEcCtD
Lidocaine—Back pain—Methotrexate—muscle cancer	0.00031	0.00185	CcSEcCtD
Lidocaine—Visual impairment—Doxorubicin—muscle cancer	0.000307	0.00183	CcSEcCtD
Lidocaine—Vision blurred—Methotrexate—muscle cancer	0.000302	0.0018	CcSEcCtD
Lidocaine—Eye disorder—Doxorubicin—muscle cancer	0.000298	0.00178	CcSEcCtD
Lidocaine—Tinnitus—Doxorubicin—muscle cancer	0.000297	0.00177	CcSEcCtD
Lidocaine—Cardiac disorder—Doxorubicin—muscle cancer	0.000296	0.00176	CcSEcCtD
Lidocaine—Flushing—Doxorubicin—muscle cancer	0.000296	0.00176	CcSEcCtD
Lidocaine—SLC22A5—renal system—muscle cancer	0.000291	0.0212	CbGeAlD
Lidocaine—Angiopathy—Doxorubicin—muscle cancer	0.000289	0.00173	CcSEcCtD
Lidocaine—Dizziness—Etoposide—muscle cancer	0.000289	0.00172	CcSEcCtD
Lidocaine—Immune system disorder—Doxorubicin—muscle cancer	0.000288	0.00172	CcSEcCtD
Lidocaine—Chills—Doxorubicin—muscle cancer	0.000286	0.00171	CcSEcCtD
Lidocaine—CYP2C8—renal system—muscle cancer	0.000282	0.0205	CbGeAlD
Lidocaine—Convulsion—Methotrexate—muscle cancer	0.000278	0.00166	CcSEcCtD
Lidocaine—Vomiting—Etoposide—muscle cancer	0.000278	0.00166	CcSEcCtD
Lidocaine—Erythema—Doxorubicin—muscle cancer	0.000278	0.00166	CcSEcCtD
Lidocaine—Rash—Etoposide—muscle cancer	0.000275	0.00164	CcSEcCtD
Lidocaine—Dermatitis—Etoposide—muscle cancer	0.000275	0.00164	CcSEcCtD
Lidocaine—Headache—Etoposide—muscle cancer	0.000274	0.00163	CcSEcCtD
Lidocaine—Chest pain—Methotrexate—muscle cancer	0.000273	0.00163	CcSEcCtD
Lidocaine—Tension—Doxorubicin—muscle cancer	0.000272	0.00162	CcSEcCtD
Lidocaine—Dysgeusia—Doxorubicin—muscle cancer	0.000272	0.00162	CcSEcCtD
Lidocaine—Nervousness—Doxorubicin—muscle cancer	0.00027	0.00161	CcSEcCtD
Lidocaine—Back pain—Doxorubicin—muscle cancer	0.000269	0.0016	CcSEcCtD
Lidocaine—CYP1A2—renal system—muscle cancer	0.000264	0.0192	CbGeAlD
Lidocaine—Confusional state—Methotrexate—muscle cancer	0.000264	0.00157	CcSEcCtD
Lidocaine—Anaphylactic shock—Methotrexate—muscle cancer	0.000262	0.00156	CcSEcCtD
Lidocaine—Vision blurred—Doxorubicin—muscle cancer	0.000262	0.00156	CcSEcCtD
Lidocaine—SLC22A5—cardiac atrium—muscle cancer	0.000261	0.0189	CbGeAlD
Lidocaine—Nausea—Etoposide—muscle cancer	0.000259	0.00155	CcSEcCtD
Lidocaine—Nervous system disorder—Methotrexate—muscle cancer	0.000257	0.00153	CcSEcCtD
Lidocaine—CYP2C9—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000255	0.00501	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways in Glioblastoma—FOXO1—muscle cancer	0.000255	0.005	CbGpPWpGaD
Lidocaine—Agitation—Doxorubicin—muscle cancer	0.000255	0.00152	CcSEcCtD
Lidocaine—CYP3A5—renal system—muscle cancer	0.000254	0.0185	CbGeAlD
Lidocaine—EGFR—Bladder Cancer—VEGFA—muscle cancer	0.000253	0.00496	CbGpPWpGaD
Lidocaine—Hyperhidrosis—Methotrexate—muscle cancer	0.000253	0.00151	CcSEcCtD
Lidocaine—CYP2B6—renal system—muscle cancer	0.000253	0.0184	CbGeAlD
Lidocaine—SCN2A—Developmental Biology—MED12—muscle cancer	0.000249	0.00488	CbGpPWpGaD
Lidocaine—SCN4A—Developmental Biology—MED12—muscle cancer	0.000249	0.00488	CbGpPWpGaD
Lidocaine—EGFR—Constitutive PI3K/AKT Signaling in Cancer—FOXO1—muscle cancer	0.000246	0.00481	CbGpPWpGaD
Lidocaine—Hypotension—Methotrexate—muscle cancer	0.000244	0.00146	CcSEcCtD
Lidocaine—Loss of consciousness—Doxorubicin—muscle cancer	0.000244	0.00145	CcSEcCtD
Lidocaine—Convulsion—Doxorubicin—muscle cancer	0.000241	0.00143	CcSEcCtD
Lidocaine—EGFR—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	0.00024	0.00471	CbGpPWpGaD
Lidocaine—SCN10A—Developmental Biology—MED12—muscle cancer	0.00024	0.0047	CbGpPWpGaD
Lidocaine—Hypertension—Doxorubicin—muscle cancer	0.00024	0.00143	CcSEcCtD
Lidocaine—EGFR—Androgen receptor signaling pathway—FOXO1—muscle cancer	0.000239	0.00468	CbGpPWpGaD
Lidocaine—Chest pain—Doxorubicin—muscle cancer	0.000236	0.00141	CcSEcCtD
Lidocaine—CYP1A2—Melatonin metabolism and effects—FOXO1—muscle cancer	0.000236	0.00463	CbGpPWpGaD
Lidocaine—Anxiety—Doxorubicin—muscle cancer	0.000236	0.0014	CcSEcCtD
Lidocaine—Paraesthesia—Methotrexate—muscle cancer	0.000235	0.0014	CcSEcCtD
Lidocaine—EGFR—Aryl Hydrocarbon Receptor—PTGS2—muscle cancer	0.000234	0.00459	CbGpPWpGaD
Lidocaine—Dyspnoea—Methotrexate—muscle cancer	0.000233	0.00139	CcSEcCtD
Lidocaine—Somnolence—Methotrexate—muscle cancer	0.000233	0.00139	CcSEcCtD
Lidocaine—Confusional state—Doxorubicin—muscle cancer	0.000228	0.00136	CcSEcCtD
Lidocaine—SLC22A5—tendon—muscle cancer	0.000227	0.0165	CbGeAlD
Lidocaine—Anaphylactic shock—Doxorubicin—muscle cancer	0.000227	0.00135	CcSEcCtD
Lidocaine—Oedema—Doxorubicin—muscle cancer	0.000227	0.00135	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Methotrexate—muscle cancer	0.000226	0.00135	CcSEcCtD
Lidocaine—EGFR—Signaling by SCF-KIT—FOXO4—muscle cancer	0.000224	0.00439	CbGpPWpGaD
Lidocaine—Pain—Methotrexate—muscle cancer	0.000224	0.00133	CcSEcCtD
Lidocaine—Shock—Doxorubicin—muscle cancer	0.000223	0.00133	CcSEcCtD
Lidocaine—Nervous system disorder—Doxorubicin—muscle cancer	0.000222	0.00132	CcSEcCtD
Lidocaine—EGFR—PI-3K cascade—FOXO1—muscle cancer	0.000221	0.00434	CbGpPWpGaD
Lidocaine—Hyperhidrosis—Doxorubicin—muscle cancer	0.000219	0.00131	CcSEcCtD
Lidocaine—EGFR—PI3K/AKT activation—FOXO1—muscle cancer	0.000216	0.00423	CbGpPWpGaD
Lidocaine—Feeling abnormal—Methotrexate—muscle cancer	0.000216	0.00129	CcSEcCtD
Lidocaine—EGFR—GAB1 signalosome—FOXO1—muscle cancer	0.000214	0.0042	CbGpPWpGaD
Lidocaine—EGFR—Downstream signaling of activated FGFR—FOXO4—muscle cancer	0.000214	0.0042	CbGpPWpGaD
Lidocaine—EGFR—ErbB Signaling Pathway—MDM2—muscle cancer	0.000214	0.00419	CbGpPWpGaD
Lidocaine—Hypotension—Doxorubicin—muscle cancer	0.000212	0.00126	CcSEcCtD
Lidocaine—SLC22A5—vagina—muscle cancer	0.000211	0.0153	CbGeAlD
Lidocaine—EGFR—Signaling by ERBB4—FOXO4—muscle cancer	0.000211	0.00413	CbGpPWpGaD
Lidocaine—EGFR—Role of LAT2/NTAL/LAB on calcium mobilization—FOXO1—muscle cancer	0.000209	0.0041	CbGpPWpGaD
Lidocaine—Urticaria—Methotrexate—muscle cancer	0.000208	0.00124	CcSEcCtD
Lidocaine—EGFR—Signaling events mediated by TCPTP—VEGFA—muscle cancer	0.000207	0.00405	CbGpPWpGaD
Lidocaine—CYP2C8—vagina—muscle cancer	0.000204	0.0148	CbGeAlD
Lidocaine—Paraesthesia—Doxorubicin—muscle cancer	0.000203	0.00121	CcSEcCtD
Lidocaine—Dyspnoea—Doxorubicin—muscle cancer	0.000202	0.0012	CcSEcCtD
Lidocaine—EGFR—Downstream signal transduction—FOXO4—muscle cancer	0.000201	0.00395	CbGpPWpGaD
Lidocaine—Somnolence—Doxorubicin—muscle cancer	0.000201	0.0012	CcSEcCtD
Lidocaine—EGFR—EGF/EGFR Signaling Pathway—FOXO4—muscle cancer	0.0002	0.00393	CbGpPWpGaD
Lidocaine—EGFR—Signaling by FGFR—FOXO4—muscle cancer	0.0002	0.00393	CbGpPWpGaD
Lidocaine—EGFR—Signaling by ERBB2—FOXO4—muscle cancer	0.000199	0.00391	CbGpPWpGaD
Lidocaine—EGFR—DAP12 signaling—FOXO4—muscle cancer	0.000198	0.00389	CbGpPWpGaD
Lidocaine—EGFR—Downstream signaling events of B Cell Receptor (BCR)—FOXO4—muscle cancer	0.000196	0.00383	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—MYOG—muscle cancer	0.000196	0.00383	CbGpPWpGaD
Lidocaine—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000196	0.00117	CcSEcCtD
Lidocaine—Pain—Doxorubicin—muscle cancer	0.000194	0.00116	CcSEcCtD
Lidocaine—Hypersensitivity—Methotrexate—muscle cancer	0.000193	0.00115	CcSEcCtD
Lidocaine—EGFR—Gastric Cancer Network 2—TP53—muscle cancer	0.000191	0.00375	CbGpPWpGaD
Lidocaine—EGFR—Bladder Cancer—TP53—muscle cancer	0.000191	0.00375	CbGpPWpGaD
Lidocaine—CYP3A4—renal system—muscle cancer	0.000191	0.0139	CbGeAlD
Lidocaine—SLC22A5—testis—muscle cancer	0.000188	0.0137	CbGeAlD
Lidocaine—CYP2D6—renal system—muscle cancer	0.000188	0.0137	CbGeAlD
Lidocaine—Asthenia—Methotrexate—muscle cancer	0.000188	0.00112	CcSEcCtD
Lidocaine—EGFR—Constitutive PI3K/AKT Signaling in Cancer—KIT—muscle cancer	0.000187	0.00367	CbGpPWpGaD
Lidocaine—EGFR—DAP12 interactions—FOXO4—muscle cancer	0.000187	0.00366	CbGpPWpGaD
Lidocaine—EGFR—Signaling by FGFR in disease—FOXO4—muscle cancer	0.000187	0.00366	CbGpPWpGaD
Lidocaine—EGFR—Fc epsilon receptor (FCERI) signaling—FOXO4—muscle cancer	0.000187	0.00366	CbGpPWpGaD
Lidocaine—Feeling abnormal—Doxorubicin—muscle cancer	0.000187	0.00111	CcSEcCtD
Lidocaine—EGFR—Signaling by EGFR—FOXO4—muscle cancer	0.000185	0.00363	CbGpPWpGaD
Lidocaine—EGFR—Aryl Hydrocarbon Receptor—VEGFA—muscle cancer	0.000185	0.00362	CbGpPWpGaD
Lidocaine—SCN5A—Developmental Biology—MYOD1—muscle cancer	0.000185	0.00362	CbGpPWpGaD
Lidocaine—CYP3A5—vagina—muscle cancer	0.000184	0.0134	CbGeAlD
Lidocaine—EGFR—Signaling by EGFR in Cancer—FOXO4—muscle cancer	0.000183	0.00359	CbGpPWpGaD
Lidocaine—CYP2B6—vagina—muscle cancer	0.000183	0.0133	CbGeAlD
Lidocaine—EGFR—Signaling by PDGF—FOXO4—muscle cancer	0.000183	0.00358	CbGpPWpGaD
Lidocaine—CYP2C8—testis—muscle cancer	0.000182	0.0132	CbGeAlD
Lidocaine—Urticaria—Doxorubicin—muscle cancer	0.00018	0.00107	CcSEcCtD
Lidocaine—ABCB1—embryo—muscle cancer	0.000179	0.013	CbGeAlD
Lidocaine—EGFR—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	0.000176	0.00344	CbGpPWpGaD
Lidocaine—Dizziness—Methotrexate—muscle cancer	0.000173	0.00103	CcSEcCtD
Lidocaine—EGFR—B Cell Activation—FOXO4—muscle cancer	0.000173	0.00339	CbGpPWpGaD
Lidocaine—CYP2B6—head—muscle cancer	0.000169	0.0123	CbGeAlD
Lidocaine—SCN5A—Developmental Biology—MED12—muscle cancer	0.000169	0.00331	CbGpPWpGaD
Lidocaine—EGFR—PI-3K cascade—KIT—muscle cancer	0.000169	0.0033	CbGpPWpGaD
Lidocaine—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000168	0.0033	CbGpPWpGaD
Lidocaine—Hypersensitivity—Doxorubicin—muscle cancer	0.000167	0.000995	CcSEcCtD
Lidocaine—Vomiting—Methotrexate—muscle cancer	0.000166	0.000992	CcSEcCtD
Lidocaine—EGFR—Signaling by SCF-KIT—FOXO1—muscle cancer	0.000165	0.00324	CbGpPWpGaD
Lidocaine—EGFR—NGF signalling via TRKA from the plasma membrane—FOXO4—muscle cancer	0.000165	0.00324	CbGpPWpGaD
Lidocaine—Rash—Methotrexate—muscle cancer	0.000165	0.000984	CcSEcCtD
Lidocaine—Dermatitis—Methotrexate—muscle cancer	0.000165	0.000983	CcSEcCtD
Lidocaine—EGFR—PI3K/AKT activation—KIT—muscle cancer	0.000165	0.00322	CbGpPWpGaD
Lidocaine—Headache—Methotrexate—muscle cancer	0.000164	0.000977	CcSEcCtD
Lidocaine—CYP2B6—testis—muscle cancer	0.000163	0.0119	CbGeAlD
Lidocaine—EGFR—GAB1 signalosome—KIT—muscle cancer	0.000163	0.0032	CbGpPWpGaD
Lidocaine—Asthenia—Doxorubicin—muscle cancer	0.000163	0.000969	CcSEcCtD
Lidocaine—EGFR—Role of LAT2/NTAL/LAB on calcium mobilization—KIT—muscle cancer	0.00016	0.00313	CbGpPWpGaD
Lidocaine—EGFR—Downstream signaling of activated FGFR—FOXO1—muscle cancer	0.000158	0.0031	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways in Glioblastoma—CDKN2A—muscle cancer	0.000158	0.00309	CbGpPWpGaD
Lidocaine—EGFR—Integrated Breast Cancer Pathway—FOXO1—muscle cancer	0.000157	0.00307	CbGpPWpGaD
Lidocaine—EGFR—Signaling by ERBB4—FOXO1—muscle cancer	0.000156	0.00305	CbGpPWpGaD
Lidocaine—Nausea—Methotrexate—muscle cancer	0.000155	0.000927	CcSEcCtD
Lidocaine—CYP2A6—Fluoropyrimidine Activity—TP53—muscle cancer	0.000154	0.00302	CbGpPWpGaD
Lidocaine—EGFR—SHP2 signaling—VEGFA—muscle cancer	0.000153	0.00301	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways in Glioblastoma—MDM2—muscle cancer	0.000153	0.003	CbGpPWpGaD
Lidocaine—Dizziness—Doxorubicin—muscle cancer	0.00015	0.000893	CcSEcCtD
Lidocaine—EGFR—Downstream signal transduction—FOXO1—muscle cancer	0.000149	0.00291	CbGpPWpGaD
Lidocaine—SCN9A—Developmental Biology—FOXO1—muscle cancer	0.000149	0.00291	CbGpPWpGaD
Lidocaine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—muscle cancer	0.000148	0.0029	CbGpPWpGaD
Lidocaine—EGFR—Signaling by FGFR—FOXO1—muscle cancer	0.000148	0.0029	CbGpPWpGaD
Lidocaine—EGFR—EGF/EGFR Signaling Pathway—FOXO1—muscle cancer	0.000148	0.0029	CbGpPWpGaD
Lidocaine—EGFR—Constitutive PI3K/AKT Signaling in Cancer—MDM2—muscle cancer	0.000147	0.00289	CbGpPWpGaD
Lidocaine—EGFR—Signaling by ERBB2—FOXO1—muscle cancer	0.000147	0.00289	CbGpPWpGaD
Lidocaine—EGFR—DAP12 signaling—FOXO1—muscle cancer	0.000147	0.00287	CbGpPWpGaD
Lidocaine—EGFR—Downstream signaling events of B Cell Receptor (BCR)—FOXO1—muscle cancer	0.000144	0.00283	CbGpPWpGaD
Lidocaine—Vomiting—Doxorubicin—muscle cancer	0.000144	0.000859	CcSEcCtD
Lidocaine—EGFR—Androgen receptor signaling pathway—MDM2—muscle cancer	0.000143	0.00281	CbGpPWpGaD
Lidocaine—Rash—Doxorubicin—muscle cancer	0.000143	0.000852	CcSEcCtD
Lidocaine—Dermatitis—Doxorubicin—muscle cancer	0.000143	0.000851	CcSEcCtD
Lidocaine—SCN3A—Developmental Biology—FOXO1—muscle cancer	0.000142	0.00279	CbGpPWpGaD
Lidocaine—Headache—Doxorubicin—muscle cancer	0.000142	0.000846	CcSEcCtD
Lidocaine—EGFR—Signaling by FGFR in disease—FOXO1—muscle cancer	0.000138	0.0027	CbGpPWpGaD
Lidocaine—EGFR—Fc epsilon receptor (FCERI) signaling—FOXO1—muscle cancer	0.000138	0.0027	CbGpPWpGaD
Lidocaine—EGFR—DAP12 interactions—FOXO1—muscle cancer	0.000138	0.0027	CbGpPWpGaD
Lidocaine—SCN2A—Developmental Biology—FOXO1—muscle cancer	0.000137	0.00268	CbGpPWpGaD
Lidocaine—SCN4A—Developmental Biology—FOXO1—muscle cancer	0.000137	0.00268	CbGpPWpGaD
Lidocaine—EGFR—Signaling by EGFR—FOXO1—muscle cancer	0.000137	0.00268	CbGpPWpGaD
Lidocaine—EGFR—Signaling by EGFR in Cancer—FOXO1—muscle cancer	0.000135	0.00265	CbGpPWpGaD
Lidocaine—ABCB1—renal system—muscle cancer	0.000135	0.00982	CbGeAlD
Lidocaine—EGFR—Signaling by PDGF—FOXO1—muscle cancer	0.000135	0.00264	CbGpPWpGaD
Lidocaine—Nausea—Doxorubicin—muscle cancer	0.000135	0.000802	CcSEcCtD
Lidocaine—EGFR—PI-3K cascade—MDM2—muscle cancer	0.000133	0.0026	CbGpPWpGaD
Lidocaine—SCN10A—Developmental Biology—FOXO1—muscle cancer	0.000132	0.00258	CbGpPWpGaD
Lidocaine—EGFR—PI3K/AKT activation—MDM2—muscle cancer	0.00013	0.00254	CbGpPWpGaD
Lidocaine—EGFR—GAB1 signalosome—MDM2—muscle cancer	0.000129	0.00252	CbGpPWpGaD
Lidocaine—EGFR—B Cell Activation—FOXO1—muscle cancer	0.000128	0.0025	CbGpPWpGaD
Lidocaine—EGFR—Signaling by NGF—FOXO4—muscle cancer	0.000127	0.00249	CbGpPWpGaD
Lidocaine—CYP2C8—Arachidonic acid metabolism—PTGS2—muscle cancer	0.000127	0.00249	CbGpPWpGaD
Lidocaine—EGFR—Signaling by SCF-KIT—KIT—muscle cancer	0.000126	0.00247	CbGpPWpGaD
Lidocaine—CYP2D6—head—muscle cancer	0.000126	0.00913	CbGeAlD
Lidocaine—EGFR—Role of LAT2/NTAL/LAB on calcium mobilization—MDM2—muscle cancer	0.000126	0.00246	CbGpPWpGaD
Lidocaine—EGFR—ErbB Signaling Pathway—TP53—muscle cancer	0.000123	0.0024	CbGpPWpGaD
Lidocaine—EGFR—NGF signalling via TRKA from the plasma membrane—FOXO1—muscle cancer	0.000122	0.00239	CbGpPWpGaD
Lidocaine—CYP2D6—testis—muscle cancer	0.000121	0.00882	CbGeAlD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	0.000121	0.00238	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—MYOD1—muscle cancer	0.000121	0.00237	CbGpPWpGaD
Lidocaine—EGFR—Downstream signaling of activated FGFR—KIT—muscle cancer	0.000121	0.00236	CbGpPWpGaD
Lidocaine—EGFR—Signaling by ERBB4—KIT—muscle cancer	0.000119	0.00233	CbGpPWpGaD
Lidocaine—EGFR—Downstream signal transduction—KIT—muscle cancer	0.000113	0.00222	CbGpPWpGaD
Lidocaine—EGFR—Signaling by FGFR—KIT—muscle cancer	0.000113	0.00221	CbGpPWpGaD
Lidocaine—EGFR—Signaling by ERBB2—KIT—muscle cancer	0.000112	0.0022	CbGpPWpGaD
Lidocaine—EGFR—DAP12 signaling—KIT—muscle cancer	0.000112	0.00219	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—MED12—muscle cancer	0.000111	0.00217	CbGpPWpGaD
Lidocaine—EGFR—Spinal Cord Injury—PTGS2—muscle cancer	0.00011	0.00216	CbGpPWpGaD
Lidocaine—EGFR—Downstream signaling events of B Cell Receptor (BCR)—KIT—muscle cancer	0.00011	0.00216	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—FH—muscle cancer	0.000108	0.00212	CbGpPWpGaD
Lidocaine—SCN5A—SIDS Susceptibility Pathways—VEGFA—muscle cancer	0.000106	0.00208	CbGpPWpGaD
Lidocaine—EGFR—Signaling by FGFR in disease—KIT—muscle cancer	0.000105	0.00206	CbGpPWpGaD
Lidocaine—EGFR—DAP12 interactions—KIT—muscle cancer	0.000105	0.00206	CbGpPWpGaD
Lidocaine—EGFR—Fc epsilon receptor (FCERI) signaling—KIT—muscle cancer	0.000105	0.00206	CbGpPWpGaD
Lidocaine—EGFR—Signaling by EGFR—KIT—muscle cancer	0.000104	0.00204	CbGpPWpGaD
Lidocaine—CYP2C9—Arachidonic acid metabolism—PTGS2—muscle cancer	0.000103	0.00203	CbGpPWpGaD
Lidocaine—EGFR—Rac1/Pak1/p38/MMP-2 pathway—TP53—muscle cancer	0.000103	0.00202	CbGpPWpGaD
Lidocaine—EGFR—Signaling by EGFR in Cancer—KIT—muscle cancer	0.000103	0.00202	CbGpPWpGaD
Lidocaine—EGFR—Signaling by PDGF—KIT—muscle cancer	0.000103	0.00201	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—CD34—muscle cancer	0.000102	0.00201	CbGpPWpGaD
Lidocaine—ABCB1—bone marrow—muscle cancer	0.000102	0.00742	CbGeAlD
Lidocaine—EGFR—Direct p53 effectors—MDM2—muscle cancer	9.98e-05	0.00196	CbGpPWpGaD
Lidocaine—EGFR—Signaling by SCF-KIT—MDM2—muscle cancer	9.93e-05	0.00194	CbGpPWpGaD
Lidocaine—CYP1A2—Tryptophan metabolism—MDM2—muscle cancer	9.8e-05	0.00192	CbGpPWpGaD
Lidocaine—ABCB1—vagina—muscle cancer	9.79e-05	0.00711	CbGeAlD
Lidocaine—EGFR—B Cell Activation—KIT—muscle cancer	9.72e-05	0.00191	CbGpPWpGaD
Lidocaine—SCN9A—Axon guidance—VEGFA—muscle cancer	9.5e-05	0.00186	CbGpPWpGaD
Lidocaine—EGFR—Downstream signaling of activated FGFR—MDM2—muscle cancer	9.5e-05	0.00186	CbGpPWpGaD
Lidocaine—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—muscle cancer	9.45e-05	0.00185	CbGpPWpGaD
Lidocaine—EGFR—Integrated Breast Cancer Pathway—MDM2—muscle cancer	9.4e-05	0.00184	CbGpPWpGaD
Lidocaine—EGFR—Signaling by NGF—FOXO1—muscle cancer	9.39e-05	0.00184	CbGpPWpGaD
Lidocaine—EGFR—Signaling by ERBB4—MDM2—muscle cancer	9.35e-05	0.00183	CbGpPWpGaD
Lidocaine—EGFR—NGF signalling via TRKA from the plasma membrane—KIT—muscle cancer	9.31e-05	0.00182	CbGpPWpGaD
Lidocaine—SCN5A—Developmental Biology—FOXO1—muscle cancer	9.27e-05	0.00182	CbGpPWpGaD
Lidocaine—SCN3A—Axon guidance—VEGFA—muscle cancer	9.09e-05	0.00178	CbGpPWpGaD
Lidocaine—ABCB1—head—muscle cancer	9.04e-05	0.00657	CbGeAlD
Lidocaine—EGFR—Downstream signal transduction—MDM2—muscle cancer	8.93e-05	0.00175	CbGpPWpGaD
Lidocaine—EGFR—Signaling by FGFR—MDM2—muscle cancer	8.88e-05	0.00174	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	8.87e-05	0.00174	CbGpPWpGaD
Lidocaine—EGFR—Signaling by ERBB2—MDM2—muscle cancer	8.84e-05	0.00173	CbGpPWpGaD
Lidocaine—CYP1A2—Arachidonic acid metabolism—PTGS2—muscle cancer	8.84e-05	0.00173	CbGpPWpGaD
Lidocaine—EGFR—DAP12 signaling—MDM2—muscle cancer	8.8e-05	0.00172	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways in Glioblastoma—TP53—muscle cancer	8.79e-05	0.00172	CbGpPWpGaD
Lidocaine—ABCB1—testis—muscle cancer	8.74e-05	0.00635	CbGeAlD
Lidocaine—SCN4A—Axon guidance—VEGFA—muscle cancer	8.73e-05	0.00171	CbGpPWpGaD
Lidocaine—SCN2A—Axon guidance—VEGFA—muscle cancer	8.73e-05	0.00171	CbGpPWpGaD
Lidocaine—EGFR—Downstream signaling events of B Cell Receptor (BCR)—MDM2—muscle cancer	8.67e-05	0.0017	CbGpPWpGaD
Lidocaine—SCN10A—Axon guidance—VEGFA—muscle cancer	8.42e-05	0.00165	CbGpPWpGaD
Lidocaine—EGFR—Signaling by FGFR in disease—MDM2—muscle cancer	8.28e-05	0.00162	CbGpPWpGaD
Lidocaine—EGFR—DAP12 interactions—MDM2—muscle cancer	8.28e-05	0.00162	CbGpPWpGaD
Lidocaine—EGFR—Fc epsilon receptor (FCERI) signaling—MDM2—muscle cancer	8.28e-05	0.00162	CbGpPWpGaD
Lidocaine—EGFR—Signaling by EGFR—MDM2—muscle cancer	8.2e-05	0.00161	CbGpPWpGaD
Lidocaine—EGFR—Signaling by EGFR in Cancer—MDM2—muscle cancer	8.13e-05	0.00159	CbGpPWpGaD
Lidocaine—EGFR—Signaling by PDGF—MDM2—muscle cancer	8.09e-05	0.00159	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—KIDINS220—muscle cancer	8.07e-05	0.00158	CbGpPWpGaD
Lidocaine—EGFR—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	7.79e-05	0.00153	CbGpPWpGaD
Lidocaine—EGFR—B Cell Activation—MDM2—muscle cancer	7.66e-05	0.0015	CbGpPWpGaD
Lidocaine—CYP3A4—Tryptophan metabolism—MDM2—muscle cancer	7.56e-05	0.00148	CbGpPWpGaD
Lidocaine—EGFR—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	7.51e-05	0.00147	CbGpPWpGaD
Lidocaine—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—muscle cancer	7.44e-05	0.00146	CbGpPWpGaD
Lidocaine—EGFR—NGF signalling via TRKA from the plasma membrane—MDM2—muscle cancer	7.33e-05	0.00144	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—FOXO4—muscle cancer	7.26e-05	0.00142	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—FH—muscle cancer	7.2e-05	0.00141	CbGpPWpGaD
Lidocaine—EGFR—Signaling by NGF—KIT—muscle cancer	7.16e-05	0.0014	CbGpPWpGaD
Lidocaine—EGFR—Integrated Breast Cancer Pathway—VEGFA—muscle cancer	7.14e-05	0.0014	CbGpPWpGaD
Lidocaine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—muscle cancer	6.98e-05	0.00137	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—FOXO4—muscle cancer	6.97e-05	0.00136	CbGpPWpGaD
Lidocaine—SCN9A—Developmental Biology—VEGFA—muscle cancer	6.78e-05	0.00133	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—FH—muscle cancer	6.6e-05	0.00129	CbGpPWpGaD
Lidocaine—EGFR—Spinal Cord Injury—TP53—muscle cancer	6.57e-05	0.00129	CbGpPWpGaD
Lidocaine—SCN3A—Developmental Biology—VEGFA—muscle cancer	6.48e-05	0.00127	CbGpPWpGaD
Lidocaine—SCN4A—Developmental Biology—VEGFA—muscle cancer	6.23e-05	0.00122	CbGpPWpGaD
Lidocaine—SCN2A—Developmental Biology—VEGFA—muscle cancer	6.23e-05	0.00122	CbGpPWpGaD
Lidocaine—EGFR—Immune System—CD34—muscle cancer	6.22e-05	0.00122	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—MED12—muscle cancer	6.12e-05	0.0012	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—FOXO1—muscle cancer	6.07e-05	0.00119	CbGpPWpGaD
Lidocaine—ABCB1—Allograft Rejection—VEGFA—muscle cancer	6.05e-05	0.00118	CbGpPWpGaD
Lidocaine—SCN10A—Developmental Biology—VEGFA—muscle cancer	6.01e-05	0.00118	CbGpPWpGaD
Lidocaine—EGFR—Focal Adhesion—VEGFA—muscle cancer	5.94e-05	0.00116	CbGpPWpGaD
Lidocaine—SCN5A—Axon guidance—VEGFA—muscle cancer	5.92e-05	0.00116	CbGpPWpGaD
Lidocaine—EGFR—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	5.91e-05	0.00116	CbGpPWpGaD
Lidocaine—EGFR—Direct p53 effectors—TP53—muscle cancer	5.73e-05	0.00112	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—MED12—muscle cancer	5.72e-05	0.00112	CbGpPWpGaD
Lidocaine—EGFR—Signaling by NGF—MDM2—muscle cancer	5.64e-05	0.0011	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—ENO2—muscle cancer	5.58e-05	0.00109	CbGpPWpGaD
Lidocaine—EGFR—Integrated Breast Cancer Pathway—TP53—muscle cancer	5.39e-05	0.00106	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—PTCH1—muscle cancer	5.38e-05	0.00105	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—FOXO1—muscle cancer	5.36e-05	0.00105	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—FH—muscle cancer	5.32e-05	0.00104	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—FH—muscle cancer	5.2e-05	0.00102	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—FOXO1—muscle cancer	5.15e-05	0.00101	CbGpPWpGaD
Lidocaine—EGFR—MAPK Signaling Pathway—TP53—muscle cancer	4.95e-05	0.00097	CbGpPWpGaD
Lidocaine—EGFR—Disease—ENO2—muscle cancer	4.79e-05	0.000938	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—MED12—muscle cancer	4.65e-05	0.000912	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—CNR1—muscle cancer	4.54e-05	0.000889	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—FH—muscle cancer	4.51e-05	0.000883	CbGpPWpGaD
Lidocaine—EGFR—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	4.47e-05	0.000875	CbGpPWpGaD
Lidocaine—EGFR—Disease—HMGA1—muscle cancer	4.35e-05	0.000852	CbGpPWpGaD
Lidocaine—EGFR—Immune System—FOXO4—muscle cancer	4.23e-05	0.000828	CbGpPWpGaD
Lidocaine—SCN5A—Developmental Biology—VEGFA—muscle cancer	4.22e-05	0.000827	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—KIT—muscle cancer	4.08e-05	0.0008	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—MED12—muscle cancer	4.07e-05	0.000797	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—MED12—muscle cancer	3.98e-05	0.000779	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	3.93e-05	0.00077	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—FH—muscle cancer	3.93e-05	0.000769	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—KIT—muscle cancer	3.92e-05	0.000768	CbGpPWpGaD
Lidocaine—EGFR—Disease—FOXO4—muscle cancer	3.9e-05	0.000764	CbGpPWpGaD
Lidocaine—EGFR—Axon guidance—VEGFA—muscle cancer	3.87e-05	0.000759	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	3.79e-05	0.000742	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—MED12—muscle cancer	3.73e-05	0.000731	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—ENO2—muscle cancer	3.71e-05	0.000727	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—FH—muscle cancer	3.7e-05	0.000725	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—FH—muscle cancer	3.67e-05	0.000719	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—ENO2—muscle cancer	3.4e-05	0.000666	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—MDM2—muscle cancer	3.22e-05	0.00063	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—PTCH1—muscle cancer	3.18e-05	0.000622	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—FH—muscle cancer	3.13e-05	0.000614	CbGpPWpGaD
Lidocaine—EGFR—Immune System—FOXO1—muscle cancer	3.12e-05	0.000611	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—MDM2—muscle cancer	3.09e-05	0.000605	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—MED12—muscle cancer	3.01e-05	0.000589	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	2.98e-05	0.000585	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—MED12—muscle cancer	2.94e-05	0.000576	CbGpPWpGaD
Lidocaine—EGFR—Disease—FOXO1—muscle cancer	2.88e-05	0.000564	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—VEGFA—muscle cancer	2.76e-05	0.000542	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—ENO2—muscle cancer	2.74e-05	0.000537	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—FOXO4—muscle cancer	2.73e-05	0.000535	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CNR1—muscle cancer	2.68e-05	0.000525	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—ENO2—muscle cancer	2.68e-05	0.000525	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—MED12—muscle cancer	2.55e-05	0.000499	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—FH—muscle cancer	2.42e-05	0.000474	CbGpPWpGaD
Lidocaine—EGFR—Immune System—KIT—muscle cancer	2.38e-05	0.000466	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—ENO2—muscle cancer	2.32e-05	0.000455	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	2.26e-05	0.000442	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—MED12—muscle cancer	2.22e-05	0.000435	CbGpPWpGaD
Lidocaine—EGFR—Disease—KIT—muscle cancer	2.2e-05	0.00043	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—IGF2—muscle cancer	2.19e-05	0.00043	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—MED12—muscle cancer	2.09e-05	0.00041	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—MED12—muscle cancer	2.07e-05	0.000406	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—ENO2—muscle cancer	2.02e-05	0.000396	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—FOXO1—muscle cancer	2.02e-05	0.000395	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—PTGS2—muscle cancer	1.94e-05	0.000381	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—ENO2—muscle cancer	1.91e-05	0.000373	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—ENO2—muscle cancer	1.89e-05	0.00037	CbGpPWpGaD
Lidocaine—EGFR—Immune System—MDM2—muscle cancer	1.87e-05	0.000367	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	1.82e-05	0.000356	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—MED12—muscle cancer	1.77e-05	0.000347	CbGpPWpGaD
Lidocaine—EGFR—Disease—MDM2—muscle cancer	1.73e-05	0.000339	CbGpPWpGaD
Lidocaine—EGFR—Disease—PTGS2—muscle cancer	1.67e-05	0.000327	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—ENO2—muscle cancer	1.61e-05	0.000316	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—KIT—muscle cancer	1.54e-05	0.000301	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	1.48e-05	0.00029	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—MED12—muscle cancer	1.37e-05	0.000268	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PTGS2—muscle cancer	1.29e-05	0.000253	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	1.26e-05	0.000247	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—ENO2—muscle cancer	1.25e-05	0.000244	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—MDM2—muscle cancer	1.21e-05	0.000237	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PTGS2—muscle cancer	1.18e-05	0.000232	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PTGS2—muscle cancer	9.55e-06	0.000187	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PTGS2—muscle cancer	9.34e-06	0.000183	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—VEGFA—muscle cancer	9.19e-06	0.00018	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PTGS2—muscle cancer	8.09e-06	0.000158	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PTGS2—muscle cancer	7.05e-06	0.000138	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—TP53—muscle cancer	6.95e-06	0.000136	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PTGS2—muscle cancer	6.64e-06	0.00013	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PTGS2—muscle cancer	6.58e-06	0.000129	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PTGS2—muscle cancer	5.62e-06	0.00011	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PTGS2—muscle cancer	4.34e-06	8.5e-05	CbGpPWpGaD
